



Most-Probable-Number-Based Minimum Duration of Killing Assay for Determining the Spectrum of Rifampicin Susceptibility in Clinical *Mycobacterium tuberculosis* Isolates

Srinivasan Vijay,^{a,b} Hoang Ngoc Nhung,^a Nguyen Le Hoai Bao,^a Do Dang Anh Thu,^a Le Pham Tien Trieu,^a Nguyen Hoan Phu,^{a,c} Guy E. Thwaites,^{a,b} Babak Javid,^{d,e,f} Nguyen T. T. Thuong^{a,b}

^aOxford University Clinical Research Unit, Ho Chi Minh City, Vietnam

^bCentre for Tropical Medicine and Global Health, Nuffield Department of Medicine, University of Oxford, Oxford, United Kingdom

^cSchool of Medicine, Vietnam National University of Ho Chi Minh City, Ho Chi Minh City, Vietnam

^dCentre for Infectious Diseases and Research, Tsinghua University School of Medicine, Beijing, China

^eBeijing Advanced Innovation Center in Structural Biology, Beijing, China

^fDivision of Experimental Medicine, University of California, San Francisco, California, USA

Srinivasan Vijay and Hoang Ngoc Nhung contributed equally to this work. Author order was based on decreasing seniority.

ABSTRACT Accurate antibiotic susceptibility testing is essential for successful tuberculosis treatment. Recent studies have highlighted the limitations of MIC-based phenotypic susceptibility methods in detecting other aspects of antibiotic susceptibilities in bacteria. Duration and peak of antibiotic exposure, at or above the MIC required for killing the bacterial population, has emerged as another important factor for determining antibiotic susceptibility. This is broadly defined as antibiotic tolerance. Antibiotic tolerance can further facilitate the emergence of antibiotic resistance. Currently, there are limited methods to quantify antibiotic tolerance among clinical *M. tuberculosis* isolates. In this study, we develop a most-probable-number (MPN)-based minimum duration of killing (MDK) assay to quantify the spectrum of *M. tuberculosis* rifampicin susceptibility within subpopulations based on the duration of rifampicin exposure required for killing the bacterial population. MDK₉₀₋₉₉ and MDK_{99,99} were defined as the minimum duration of antibiotic exposure at or above the MIC required for killing 90 to 99% and 99.99% of the initial (pretreatment) bacterial population, respectively. Results from the rifampicin MDK assay applied to 28 laboratory and clinical *M. tuberculosis* isolates showed that there is variation in rifampicin susceptibility among isolates. The rifampicin MDK_{99,99,99} time for isolates varied from less than 2 to 10 days. MDK was correlated with larger subpopulations of *M. tuberculosis* from clinical isolates that were rifampicin tolerant. Our study demonstrates the utility of MDK assays to measure the variation in antibiotic tolerance among clinical *M. tuberculosis* isolates and further expands clinically important aspects of antibiotic susceptibility testing.

KEYWORDS *Mycobacterium tuberculosis*, rifampicin, antibiotic tolerance assay, minimum duration of killing, most probable number, MDK, MPN, antibiotic tolerance

Tuberculosis (TB), caused by *Mycobacterium tuberculosis*, results in more than 1.5 million deaths a year (1). Although TB can be successfully treated with antibiotics, a minimum of 6 months of treatment is required (2). Relapse posttreatment and emergence of antibiotic resistance are major negative sequelae of inadequate treatment (2). Success in therapy requires the accurate determination of antibiotic susceptibility and initiation and adherence to an effective antibiotic regimen (3).

The most common measure of antibiotic susceptibility of *M. tuberculosis* isolates is

Citation Vijay S, Nhung HN, Bao NLH, Thu DDA, Trieu LPT, Phu NH, Thwaites GE, Javid B, Thuong NTT. 2021. Most-probable-number-based minimum duration of killing assay for determining the spectrum of rifampicin susceptibility in clinical *Mycobacterium tuberculosis* isolates. *Antimicrob Agents Chemother* 65:e01439-20. <https://doi.org/10.1128/AAC.01439-20>.

Copyright © 2021 Vijay et al. This is an open-access article distributed under the terms of the [Creative Commons Attribution 4.0 International license](https://creativecommons.org/licenses/by/4.0/).

Address correspondence to Nguyen T. T. Thuong, thuongnt@oucru.org.

Received 8 July 2020

Returned for modification 5 August 2020

Accepted 24 November 2020

Accepted manuscript posted online 30 November 2020

Published 17 February 2021

the MIC (4), the concentration of antibiotics that inhibits, kills, or reduces the growth of at least 99% of the bacterial population (5). The MICs for antibiotics vary between clinical *M. tuberculosis* isolates, and epidemiologically relevant MIC breakpoints are used to define *M. tuberculosis* isolates as susceptible or resistant to each antibiotic (6).

However, Colangeli et al. recently showed that MICs in the susceptible range, below the clinical cutoff for resistance, can be associated with poor treatment outcomes in TB (7). Furthermore, recent findings in other bacteria suggest that antibiotic susceptibility differences can even emerge between isolates with similar MICs due to differences in the duration of antibiotic exposure required for killing bacterial subpopulations (8). Therefore, susceptibility or resistance to an antibiotic, defined by the clinical MIC cutoff, is not the only measure of antimicrobial susceptibility, as bacterial isolates can still display widely different susceptibilities to bactericidal antibiotics, a phenomenon broadly described as antibiotic tolerance (8, 9). With antibiotic tolerance, subpopulations of bacteria that are genetically susceptible to an antibiotic are killed more slowly than the bulk population (8). Studies have identified the emergence of mutations in *M. tuberculosis* clinical isolates associated with increased levels of antibiotic tolerance (10–13). The emergence of antibiotic tolerance can further facilitate the emergence of resistance (14–17). These studies highlight limitations of reliance on clinical MIC cutoff alone as the measure of antibiotic susceptibility and the possible role of antibiotic tolerance in poor treatment progression and evolution of antibiotic resistance in *M. tuberculosis* isolates. Hence, it is important to investigate the level of antibiotic tolerance among clinical *M. tuberculosis* isolates defined as susceptible based on clinical MIC cutoffs for resistance.

One way to measure the level of antibiotic tolerance is to determine the duration of antibiotic exposure at or above MICs required for killing the majority of the bacterial population (18). Kill-curve assays allow the study of the dynamics of bacterial population killing after antibiotic exposure (19). Antibiotic-mediated killing of bacterial populations is biphasic, with an initial rapid killing of the majority population followed by a low rate of killing of minority populations, also known as tolerant and persistent bacterial populations (19). Repeated antibiotic exposure can lead to an increase in the level of antibiotic tolerance both at subpopulation and bulk population levels (11, 20). This will further increase the time required for killing the bacterial population. Recent clinical studies have shown in-host evolution of antibiotic tolerance in other pathogenic bacteria and its association with treatment complications (21).

Therefore, quantitative assays to measure the antibiotic tolerance of bacterial populations are required. Commonly used tolerance assays are based on the duration required for killing the bacterial population by antibiotics, also known as the minimum duration of killing (MDK) assay (18). The MDK assay can be used to measure both bulk population and subpopulation levels of antibiotic tolerance (18). MDK₉₀ and MDK₉₉ refer to the minimum duration required for killing 1 or 2 log₁₀ fold (90% to 99%) or the majority of the bacterial population during antibiotic exposure. Hence, MDK₉₀ or MDK₉₉ can quantify the bulk population level of antibiotic tolerance (18), whereas MDK_{99,99} determines the minimum duration required for killing 4 log₁₀ fold of the population and, assuming the tolerant subpopulation is >0.1%, quantifies the subpopulation level of antibiotic persistence (18).

Reliable and feasible methods are required to measure MDK values of clinical *M. tuberculosis* isolates to determine if there are significant variations in antibiotic tolerance among *M. tuberculosis* isolates. A critical measure used in the MDK assay is to accurately determine the viable bacterial numbers at different time points after antibiotic exposure of the bacterial culture. Usually, bacterial viability is measured by either CFU enumeration or most-probable-number (MPN) methods (22). In the MPN method, the viable bacterial numbers in culture are determined by generating 10-fold serial dilutions of the culture until limiting dilution (i.e., the dilutions show no visible bacterial growth over time) is reached. The viable bacterial number (MPN/ml) is calculated by considering that the highest dilution showing growth contains at least one viable




FIG 1 MDK assay study design. Mycobacterial cultures were grown in 50-ml tubes until the OD reached 0.4 to 0.6. This culture was diluted to an OD of 0.4 with fresh 7H9T medium. One milliliter from this culture was removed at day 0 (just before rifampicin treatment) for measuring viable bacterial numbers by serial dilution in triplicate using 96-well microtiter plates. The serially diluted microtiter plates were incubated for 1 to 2 months for determining the MPN/ml. After day 0 sampling, the remaining culture in the tube was treated with rifampicin (1 or 2 $\mu\text{g}/\text{ml}$) and incubated further. At different time points after rifampicin treatment, 1 ml rifampicin-treated culture was removed and centrifuged, and the cell pellet was washed free of antibiotic, resuspended in fresh medium, and serially diluted similarly to the day 0 procedure. The bacterial number in the original culture before and after rifampicin treatment is determined by the MPN method.

bacterium and then multiplying by the dilution factor (23). Previous study has shown that MPN and CFU methods give comparable viable counts for *M. tuberculosis* under starvation in phosphate-buffered saline (PBS) (24), whereas only the MPN method can detect differentially detectable *M. tuberculosis* cells generated under rifampicin treatment after initial starvation in PBS, as such *M. tuberculosis* cells fail to grow in the CFU method (24). Furthermore, the MPN method facilitates differentially culturable *M. tuberculosis* growth from clinical samples (25), increasing the count of viable bacteria compared to the CFU method. In addition, all serial dilutions can be simultaneously incubated in one microtiter plate in the MPN method, overcoming the laborious process of plating multiple serial dilutions to obtain countable numbers of colonies using the CFU method (26). Considering these advantages of the MPN method, we applied this method for determining bacterial viability in our MDK assay.

Given the prime importance of rifampicin in drug-sensitive tuberculosis treatment (27), we developed and tested an MPN-based MDK assay for determining the level of rifampicin tolerance among *M. tuberculosis* isolates. We applied this assay on a pilot scale to determine the spectrum of rifampicin susceptibility in 27 clinical *M. tuberculosis* isolates and identified variation in rifampicin susceptibility among these isolates, which included 7 isoniazid- and rifampicin-susceptible isolates, 19 isoniazid-resistant isolates, and 1 multidrug-resistant TB (MDR-TB) isolate, resistant to both isoniazid and rifampicin.

RESULTS

Developing an MPN-based MDK assay for determining *M. tuberculosis* rifampicin susceptibility. To develop the MDK assay and to determine rifampicin susceptibility, we initially optimized the assay by testing laboratory strains *M. tuberculosis* H37Rv and *M. bovis* BCG treated with rifampicin in mid-log phase (Fig. 1 and 2A and B).




FIG 2 MPN-based MDK assay development using laboratory mycobacterial strains *M. tuberculosis* H37Rv and *M. bovis* BCG. (A) Mid-log-phase cultures of laboratory strain H37Rv (with [+] and without [-] beads) were treated with 1 μ g/ml rifampicin, and viable bacterial numbers were measured as MPN/ml just before rifampicin treatment (day 0) and each day after rifampicin treatment for 3 days. (B) Survival fraction and MDK₉₉ of *M. tuberculosis* H37Rv and *M. bovis* BCG. The black dashed horizontal line indicates a 2- \log_{10} fold reduction in survival fraction (MDK₉₉) compared to day 0. Dashed colored vertical lines indicate the MDK₉₉ time for individual isolates with or without beads. The data are average MPN/ml at each day for 4 experiments. *M. tuberculosis* H37Rv experiments with and without beads are marked with different colors.

Both laboratory strains showed rapid killing with 1 μ g/ml rifampicin treatment, the cut-off concentration used for defining susceptible and resistant isolates in mycobacterial growth indicator tube (MGIT) culture for clinical isolates (28). The decrease in MPN/ml compared with day 0 in microtiter plates showed an MDK₉₉ time of less than 1 day for *M. bovis* BCG and between 2 and 3 days after rifampicin treatment for H37Rv with and without bead beating (Fig. 2B). Bead beating to remove bacterial aggregation, in addition to Tween 80 being in the culture media, marginally decreased H37Rv rifampicin tolerance compared to that of cultures with Tween 80 alone (without beads).

Factors influencing rifampicin MDK assay for *M. tuberculosis* isolates. Some of the factors that need to be considered for the rifampicin MDK assay are the influence of nutrients, such as carbon source, on *M. tuberculosis* survival and growth in the MDK assay; we determined the *M. tuberculosis* viable count in the presence or absence of glycerol by the MPN method (see Fig. S1A in the supplemental material). The results showed that the presence of glycerol in the culture medium consistently increased the MPN compared to those of cultures without glycerol, indicating the influence of carbon source on *M. tuberculosis* viable numbers.

Similarly, washing was done with 7H9T medium to minimize the changes in culture conditions for the bacterium during different steps of the MDK assay. The washing step is critical, and care should be taken to prevent bacterial cell loss during removal of supernatant. The washing must be adequate to remove rifampicin, as residual rifampicin may inhibit *M. tuberculosis* growth at undiluted or lower dilutions in MPN dilution series (Fig. S1C). These aspects were considered for standardizing optimum washing steps in the MDK assay.

In addition, initially we performed the rifampicin MDK assay using the CFU method for H37Rv (Fig. S2A). Although we observed similar patterns of kill curves for 20 days of rifampicin treatment between CFU and MPN methods (Fig. S2), the CFU method was difficult to apply to a large set of clinical *M. tuberculosis* isolates, as getting countable numbers of colonies required plating multiple serial dilutions, which became laborious. Therefore, we applied an MPN-based rifampicin MDK assay for clinical *M. tuberculosis* isolates.

Applying rifampicin MDK assay for clinical *M. tuberculosis* isolates. We then applied the MDK assay to investigate variation in rifampicin susceptibility among clinical *M. tuberculosis* isolates ($n = 27$). Clinical *M. tuberculosis* isolates were selected based on GeneXpert MTB/RIF results for rifampicin susceptibility and phenotypic drug




FIG 3 Applying rifampicin MDK assay to clinical *M. tuberculosis* isolates. (A and B) rifampicin MDK assay for mid-log-phase cultures of 6 clinical *M. tuberculosis* isolates susceptible to isoniazid and rifampicin (S1 to S6) (A), and 19 isoniazid-resistant isolates (IR1 to IR19) were treated with 2 $\mu\text{g/ml}$ (Continued on next page)

susceptibility testing (DST) by MGIT. For this assay, we included laboratory strain H37Rv (Rv), 7 isoniazid- and rifampicin-susceptible isolates (S1 to S7) (Fig. 3A), 19 isoniazid-resistant but rifampicin-susceptible isolates (IR1 to IR19) (Fig. 3B), and an MDR-TB isolate (R) (Fig. 3A and B), resistant to both isoniazid and rifampicin. For the MDK assay in clinical isolates, we used a higher rifampicin concentration of $2\ \mu\text{g/ml}$ for both H37Rv and clinical *M. tuberculosis* isolates cultured without bead beating, and survival fraction was determined by the MPN method using a single set of serial dilution at different time points (Fig. 3A to H). The increase in antibiotic concentration increased the duration of maintaining the rifampicin concentration above the clinical susceptibility cutoff of $1\ \mu\text{g/ml}$ in the medium. This extended the duration of the killing phase as well as the range of MDK for determining the rifampicin susceptibility among clinical *M. tuberculosis* isolates. Survival curves of the laboratory strain H37Rv and the MDR-TB isolate were included, with susceptible and isoniazid-resistant *M. tuberculosis* isolates, as controls for high rifampicin susceptibility and resistance, respectively (Fig. 3A and B).

All the rifampicin-susceptible *M. tuberculosis* isolates and H37Rv showed a reduction in viability, i.e., killing phase for 5 to 10 days of treatment compared with MPN/ml at day 0, whereas rifampicin-resistant MDR-TB isolates showed growth or maintenance of MPN/ml compared with day 0 values over 10 days of rifampicin treatment (Fig. 3A and B). From 5 to 10 days of rifampicin treatment, the regrowth phase was observed in most of the clinical *M. tuberculosis* isolates, potentially representing the outgrowth of *de novo* rifampicin-resistant cells (15). Since MDK time can be measured only during the killing phase of rifampicin treatment (29), the range of MDK measurements in our assay was restricted from 2 to 10 days of rifampicin treatment for isoniazid-susceptible (Fig. 3A) and -resistant isolates (Fig. 3B).

Although all the cultures were initially diluted to an optical density (OD) of 0.4, significant variation was observed in the initial MPN among clinical isolates. We observed that H37Rv showed the highest initial MPN, whereas clinical isolate initial MPN showed variation within the range of 10^4 fold (Fig. 3A and B). This variation in the initial MPN was probably due to variation in cell size heterogeneity, cell envelope modifications, and clumping among clinical *M. tuberculosis* isolates. Even though initial MPN among clinical *M. tuberculosis* isolates showed variation, we could determine the MDK time for each of the isolates based on the time required for 2- and 4-log_{10} fold reductions in the MPN compared to its respective initial MPN (Fig. 3C to H).

There was substantial variation in population and subpopulation levels of rifampicin tolerance among susceptible and isoniazid-resistant *M. tuberculosis* isolates, as determined by approximate MDK_{99} and $\text{MDK}_{99.99}$ times (Fig. 3C to H). To further confirm the robustness and reliability of the MDK assay for determining rifampicin tolerance of clinical isolates, we repeated the assay with 3 to 6 independent biological replicates of 6 strains, representing fully drug-susceptible (S7) and isoniazid-resistant (IR9, IR11, IR12, and IR13) strains and H37Rv (Fig. 3I and Fig. S3). The repeat assay fully recapitulated the observations, again revealing that 3/4 of the isoniazid-resistant isolates had longer MDK times for rifampicin than the fully drug-susceptible isolate (Fig. 3I and Fig. S3). Our data confirm the ability of the MDK assay to discriminate differences in the bulk

FIG 3 Legend (Continued)

rifampicin (B). Viable mycobacterial cell numbers were determined by the MPN method on day 0 (just before rifampicin treatment) and 5 and 10 days after rifampicin treatment. Laboratory strain H37Rv (Rv) and MDR-TB (R) isolates were used as controls for low and high rifampicin tolerance, respectively, with both susceptible and isoniazid-resistant isolates. (C and D) Normalized survival fraction of susceptible (C) and isoniazid-resistant (D) isolates to determine the MDK_{99} and $\text{MDK}_{99.99}$ times. Black solid horizontal lines indicate 2-log_{10} fold (M_{99}) and 4-log_{10} fold ($M_{99.99}$) reductions in survival fractions compared to day 0 values (normalized as 100% for susceptible and isoniazid-resistant isolates). Black dashed vertical lines show the approximate time required for 99% or 99.99% reduction in survival fraction of individual *M. tuberculosis* isolates. (E to G) Susceptible and isoniazid-resistant isolates (from panels A and B) grouped based on decreasing order of their initial MPN counts. (H) *M. tuberculosis* isolates with initial \log_{10} MPN of 6, 5, and 4 grouped together, as there were only a few isolates in each of these groups for MDK time determination. (I) Normalized survival fraction of the H37Rv subset of isoniazid-resistant (IR9, IR11, IR12, and IR13) and a susceptible isolate (S7) at 0, 2, and 5 days after rifampicin treatment to determine the MDK_{99} duration (3 to 6 biologically independent experiments). Black solid horizontal lines indicate 2-log_{10} fold (M_{99}) reduction in survival fraction compared to day 0 values (normalized as 100% for all *M. tuberculosis* strains). Dashed vertical lines show approximate times required for 99% reduction in survival fraction of individual *M. tuberculosis* isolates, except for three isoniazid-resistant isolates with high rifampicin tolerance (IR11, IR12, and IR13, M_{99} of >5 days).




FIG 4 Variation in rifampicin tolerance as determined by MDK time. (A) MDK₉₉ (M₉₉) and MDK_{99,99} (M_{99,99}) times for susceptible (S) and isoniazid-resistant (IR) isolates. (B and C) M₉₉ (B) and M_{99,99} (C) for all susceptible and isoniazid-resistant isolates combined to determine the median (50th percentile) in the first column. Median values for M₉₉ of 5 days and M_{99,99} of 10 days were used to group susceptible and isoniazid-resistant isolates with low (L-RIF < median) and high (H-RIF > median) rifampicin tolerance. Each data point represents one clinical *M. tuberculosis* isolate, and median and interquartile ranges of distributions are given (**, $P < 0.01$; ***, $P < 0.001$; ****, $P < 0.0001$; all by Mann-Whitney U test).

population and subpopulation susceptibility and tolerance to rifampicin among clinical *M. tuberculosis* isolates.

Finally, we investigated the variation in the distribution of rifampicin MDK₉₉ and MDK_{99,99} times among isoniazid-susceptible and -resistant isolates. H37Rv showed high rifampicin susceptibility, similar to the earlier observation with 1- μ g/ml rifampicin treatment, having an MDK₉₉ and MDK_{99,99} time of less than 2 and 3 days, respectively, whereas for susceptible and isoniazid-resistant clinical *M. tuberculosis* isolates, MDK₉₉ time distribution varied from 2 to >10 days and MDK_{99,99} time varied from 3 to >10 days; a value of more than 10 days indicates a high level of rifampicin tolerance beyond the detection limit of our assay (Fig. 4). There was no statistically significant difference between overall rifampicin tolerance distribution, measured as MDK₉₉ and MDK_{99,99} time, between susceptible and isoniazid-resistant groups (Mann-Whitney U test) (Fig. 4A). We used the median of MDK₉₉ (5 days) and MDK_{99,99} (10 days) distribution to group susceptible and isoniazid-resistant isolates with low (equal to or below the median) and high (above the median) rifampicin tolerance (Fig. 4A and B). All high-rifampicin-tolerance isolates were beyond the 75th percentile or above the upper detection limit of our assay (Fig. 4A and B). Out of 19 isoniazid-resistant isolates, 5 and 10 isolates showed significantly high rifampicin tolerance, as determined by MDK₉₉ and MDK_{99,99}, respectively, compared to susceptible and other isoniazid-resistant isolates (Fig. 4A and B). This further indicates the ability of the MDK assay to differentiate low and high rifampicin tolerance among clinical *M. tuberculosis* isolates.

DISCUSSION

In this study, we developed an MPN-based MDK assay for determining the spectrum of rifampicin susceptibility in clinical *M. tuberculosis* isolates. Our MDK assay can be easily adapted to study the variation in killing dynamics and determine the susceptibility level for different conditions, such as different concentrations of rifampicin, other anti-tuberculosis antibiotics, combinations of antibiotics, and host stresses or bacterial metabolic adaptations (such as different carbon sources) by changing the treatments accordingly. Our pilot-scale study indicates the presence of bulk population and subpopulation level variation in rifampicin susceptibility among clinical *M. tuberculosis* isolates, as determined by MDK₉₉ and MDK_{99,99} times, respectively.

rifampicin-susceptible clinical *M. tuberculosis* isolates (fully susceptible and isoniazid resistant, $n = 26$) show variation in MDK time, ranging from less than 2 up to 10 days and greater than 10 days, which is beyond the detection limit of our assay using

rifampicin at 2 $\mu\text{g}/\text{ml}$. This indicates the MDK assay can distinguish a spectrum of rifampicin susceptibility, ranging from highly susceptible to highly tolerant.

Tolerance or susceptibility assays require reliable methods to determine the survival fractions of bacterial populations at different durations after antibiotic exposure. Previous studies have shown that the MPN method quantitatively works as good as, and sometimes even better than, the CFU method for determining the viability of *M. tuberculosis* (24, 25). In addition, it has the advantage of incubating all serial dilutions, which is essential for determining the antibiotic tolerance among clinical *M. tuberculosis* isolates with wide variations in the spectrum of tolerance. Adopting the MPN method of the MDK assay in 96-well microtiter plates significantly reduces the labor required for testing antibiotic tolerance in large numbers of clinical isolates compared with the CFU method. Furthermore, the MPN method also reduces the time required for reading the results as the presence or absence of growth at each dilution (visual check) compared with the time required for counting colonies in the CFU method.

A striking observation of our study was the relatively increased tolerance to rifampicin in isoniazid-resistant isolates, particularly concerning MDK_{99.99}. Routine laboratory MIC testing can miss such tolerance in clinical isolates (27). Importantly, the association of high rifampicin tolerance with isoniazid resistance may further contribute to the *de novo* emergence of multidrug resistance or failure of multidrug combinational therapy (17, 30) and requires further detailed investigation. The spectrum and high level of antibiotic tolerance observed in our clinical isolates is in accordance with the *in vitro* evolution of antibiotic tolerance in laboratory strains of mycobacteria (11) and high levels of antibiotic tolerance observed in other bacteria (31).

This assay has been developed considering laboratories based in low- and middle-income countries, and the growth on the microtiter plate can be read using a simple mirror box. The viability can be detected early using fluorescence dyes to further reduce the incubation time and obtain rapid results for clinical application (32). The MDK assay will also help us to screen for phenotypic antibiotic tolerance among clinical *M. tuberculosis* isolates and identify novel genetic variants and molecular mechanisms associated with the emergence of antibiotic tolerance (10–12). In addition, the MDK assay can help to identify possible chemical agents to reverse such tolerance by increasing the antibiotics potential (16). Investigating antibiotic tolerance and its emergence in clinical *M. tuberculosis* isolates will greatly improve treatment strategies by identifying hard-to-treat phenotypes and stratifying treatment approaches (33), preventing relapse or emergence of antibiotic resistance (17, 30).

MATERIALS AND METHODS

Bacterial isolates. *M. tuberculosis* H37Rv and *M. bovis* BCG from a laboratory strain collection and clinical *M. tuberculosis* isolates from pulmonary tuberculosis patients, collected before and after treatment for a previous study (34), were revived from the archive and initially cultured in 7H9G medium (supplemented with 10% oleic acid-albumin-dextrose-catalase [OADC], 0.2% glycerol), followed by one or two subcultures in Middlebrook 7H9T medium (BD Difco, Thermo Fisher Scientific) supplemented with OADC and 0.05% Tween 80, with or without 0.2% glycerol. These cultures were used for the MDK experiments.

Mycobacterium culture for MDK assay. Mycobacterial isolates were cultured in 10 to 15 ml 7H9T medium in 50-ml tubes, with or without glass beads, in a shaking incubator at 37°C. When the culture reached an OD at 600 nm (OD₆₀₀) range of 0.4 to 0.6, acid-fast staining was done to confirm the purity of the *Mycobacterium* culture. Cultures set with glass beads were vortexed for 3 min to disrupt bacterial aggregates, as the aggregates may influence the level of antibiotic tolerance (35). Cultures in both sets of tubes, with or without glass beads, were diluted to an OD₆₀₀ of 0.4 with fresh 7H9T medium and used for the MDK assay.

rifampicin preparation. rifampicin (Sigma-Aldrich) stock solutions were prepared in dimethyl sulfoxide and filter sterilized, and aliquots were stored at –20°C for MDK assay.

Bacterial viability determination by MPN method. For the MDK assay, first the initial viability of mid-log-phase (OD₆₀₀ of 0.4) *M. tuberculosis* cultures were measured by the MPN method (0 day) by taking a 1-ml aliquot from the culture at an OD of 0.4 and harvesting the culture at 7,000 rpm for 5 min. Nine hundred microliters of supernatant was removed carefully without disturbing the bacterial cell pellet, and the cell pellet was washed once by suspending in 1 ml (1 × volume) of fresh 7H9T medium, vortexed, and recentrifuged. Nine hundred microliters of supernatant was removed, and the cell pellet again was resuspended in 1 ml fresh 7H9T medium. One hundred microliters from this 1-ml culture was

transferred to 96-well plates as an undiluted culture in triplicate for serial dilution. Ten microliters from the undiluted (10^0) culture was used for serial dilution in 90 μ l 7H9T medium up to 10^{-9} dilutions in microtiter plates (Fig. 1). Each time, new pipette tips were used for mixing and transferring culture during serial dilution. The final two wells, with 7H9T medium at the end of serial dilution after 10^{-9} , were left for sterility check without adding any mycobacterial culture (Fig. 1). The serially diluted plates were sealed by 96-well plastic adhesive seal and incubated at 37°C, without shaking, for 1 or 2 months. Immediately after initial (0 day) viability measurement, the mycobacterial cultures in the 50-ml tubes were treated with rifampicin at a final concentration of 1 or 2 μ g/ml, and cultures were further incubated at 37°C with shaking (Fig. 1). At different time points (1, 2, 3, 5, 10, 15, and 20 days, depending on the experiment) after rifampicin treatment, viable bacterial numbers were measured again by removing 1 ml from the rifampicin-treated culture, cells were washed once with 1 ml fresh 7H9T medium ($1 \times$ volume) to remove rifampicin, and the MPN assay was repeated as performed on the initial day (0 day) before rifampicin treatment (Fig. 1). In addition, we performed the rifampicin MDK assay and viability measurement using the CFU method for H37Rv. For CFU-based viability determination, the same steps were followed as those described for the MPN method, except 50- μ l aliquots from different serial dilutions were plated on 7H10 plates and incubated at 37°C, and CFU numbers were counted after 30 days of incubation.

For the MPN method, growth in 7H9T medium at the bottom of 96-well plates was recorded by the Thermo Fisher Sensititre Vizion digital MIC viewing system (Thermo Fisher Scientific, Inc.) after 15 to 20 days and 1 and 2 months of incubation (Fig. 1; see also Fig. S1 in the supplemental material). Final MPN results were calculated based on 15 to 20 days of incubation for antibiotic tolerance determination between clinical *M. tuberculosis* isolates considering different factors influencing the MPN (Fig. S1). There was some increase in MPN at 1 month (slow growth possibly due to postantibiotic effect or resuscitation of nonreplicating persisters), and drying up of wells was also observed in 96-well plates at the 1- and 2-month time points (Fig. S1). Early reading at 15 to 20 days clearly distinguished differences in the extent of growth even at the same serial dilution between *M. tuberculosis* isolates (Fig. S1A). Due to higher sensitivity in detecting differences in growth at 15 to 20 days of incubation and drying up of wells at later incubation periods, we used 15- to 20-day MPN results for calculating the survival fraction after rifampicin treatment (Fig. S1). *M. tuberculosis* viability at each time point is calculated as mean MPN/ml with 95% CI (confidence intervals) or with standard deviations. For a single set of dilution series, the MPN/ml was determined by the highest dilution showing growth multiplied by the dilution factor. Based on MPN value at each time point, survival curves were plotted to determine the killing dynamics after rifampicin treatment. The MDK₉₉ and MDK_{99.99} times were calculated based on the duration required for 99% and 99.99% reduction in the survival of the population, respectively, during the killing phase compared to the initial MPN/ml, taken as 100%.

DST. MGIT was used for phenotypic drug susceptibility testing (DST) by a Bactec MGIT 960 SIRE kit (Becton, Dickinson) according to the manufacturer's protocol. Bactec MGIT 960 SIRE DST was done for streptomycin (1.0 μ g/ml), isoniazid (0.1 μ g/ml), rifampicin (1.0 μ g/ml), and ethambutol (5.0 μ g/ml) (34).

GeneXpert MTB/RIF. For the GeneXpert MTB/RIF detection of rifampicin resistance, we followed the manufacturer's protocol using the GeneXpert instrument, GeneXpert Dx system software, and cartridge (Cepheid) (36). Briefly, 0.2 ml of decontaminated sputum was added into 2 ml of sample reagent and transferred into a test cartridge. The cartridge was inserted into the test platform of a GeneXpert instrument and post-run analyzed for detection of *M. tuberculosis* and rifampicin resistance (36).

SUPPLEMENTAL MATERIAL

Supplemental material is available online only.

SUPPLEMENTAL FILE 1, PDF file, 0.3 MB.

ACKNOWLEDGMENTS

We thank Saurabh Mishra and Carl Nathan, Department of Microbiology and Immunology at Weill Cornell Medicine, for providing the MPN calculation program.

This work was supported by the Wellcome Trust Intermediate Fellowship in Public Health and Tropical Medicine to N.T.T. (206724/Z/17/Z) and Wellcome Trust Major Overseas Program Funding to G.T. (106680/B/14/Z).

REFERENCES

- World Health Organization. 2019. Global tuberculosis report. World Health Organization, Geneva, Switzerland. <https://www.who.int/publications/item/global-tuberculosis-report-2019>
- Horsburgh CR, Jr, Barry CE, III, Lange C. 2015. Treatment of tuberculosis. *N Engl J Med* 373:2149–2160. <https://doi.org/10.1056/NEJMra1413919>.
- Vernon A, Fielding K, Savic R, Dodd L, Nahid P. 2019. The importance of adherence in tuberculosis treatment clinical trials and its relevance in explanatory and pragmatic trials. *PLoS Med* 16:e1002884. <https://doi.org/10.1371/journal.pmed.1002884>.
- Hall L, Jude KP, Clark SL, Wengenack NL. 2011. Antimicrobial susceptibility testing of *Mycobacterium tuberculosis* complex for first and second line drugs by broth dilution in a microtiter plate format. *J Vis Exp* 52:3094. <https://doi.org/10.3791/3094>.
- Parish TRD, Brown AC (ed). 2015. *Mycobacteria protocols*, 2nd ed. Humana, Totowa, NJ.
- Angeby K, Jureen P, Kahlmeter G, Hoffner SE, Schon T. 2012. Challenging a dogma: antimicrobial susceptibility testing breakpoints for *Mycobacterium tuberculosis*. *Bull World Health Organ* 90:693–698. <https://doi.org/10.2471/BLT.11.096644>.
- Colangeli R, Jedrey H, Kim S, Connell R, Ma S, Chippada Venkata UD,

- Chakravorty S, Gupta A, Sizemore EE, Diem L, Sherman DR, Okwera A, Dietze R, Boom WH, Johnson JL, MacKenzie WR, Alland D, DMID 01-009/Tuberculosis Trials Consortium Study 22 Teams. 2018. Bacterial factors that predict relapse after tuberculosis therapy. *N Engl J Med* 379:823–833. <https://doi.org/10.1056/NEJMoa1715849>.
8. Brauner A, Fridman O, Gefen O, Balaban NQ. 2016. Distinguishing between resistance, tolerance and persistence to antibiotic treatment. *Nat Rev Microbiol* 14:320–330. <https://doi.org/10.1038/nrmicro.2016.34>.
 9. Kester JC, Fortune SM. 2014. Persisters and beyond: mechanisms of phenotypic drug resistance and drug tolerance in bacteria. *Crit Rev Biochem Mol Biol* 49:91–101. <https://doi.org/10.3109/10409238.2013.869543>.
 10. Su HW, Zhu JH, Li H, Cai RJ, Ealand C, Wang X, Chen YX, Kayani MU, Zhu TF, Moradigaravand D, Huang H, Kana BD, Javid B. 2016. The essential mycobacterial amidotransferase GatCAB is a modulator of specific translational fidelity. *Nat Microbiol* 1:16147. <https://doi.org/10.1038/nmicrobiol.2016.147>.
 11. Torrey HL, Keren I, Via LE, Lee JS, Lewis K. 2016. High persister mutants in *Mycobacterium tuberculosis*. *PLoS One* 11:e0155127. <https://doi.org/10.1371/journal.pone.0155127>.
 12. Hicks ND, Yang J, Zhang X, Zhao B, Grad YH, Liu L, Ou X, Chang Z, Xia H, Zhou Y, Wang S, Dong J, Sun L, Zhu Y, Zhao Y, Jin Q, Fortune SM. 2018. Clinically prevalent mutations in *Mycobacterium tuberculosis* alter propionate metabolism and mediate multidrug tolerance. *Nat Microbiol* 3:1032–1042. <https://doi.org/10.1038/s41564-018-0218-3>.
 13. Wang BW, Zhu JH, Javid B. 2020. Clinically relevant mutations in mycobacterial LepA cause rifampicin-specific phenotypic resistance. *Sci Rep* 10:8402. <https://doi.org/10.1038/s41598-020-65308-2>.
 14. Levin-Reisman I, Ronin I, Gefen O, Braniss I, Shosh N, Balaban NQ. 2017. Antibiotic tolerance facilitates the evolution of resistance. *Science* 355:826–830. <https://doi.org/10.1126/science.aaj2191>.
 15. Sebastian J, Swaminath S, Nair RR, Jakkala K, Pradhan A, Ajitkumar P. 2017. De novo emergence of genetically resistant mutants of *Mycobacterium tuberculosis* from the persistence phase cells formed against antituberculosis drugs in vitro. *Antimicrob Agents Chemother* 61:e01343-16. <https://doi.org/10.1128/AAC.01343-16>.
 16. Chaudhuri S, Li L, Zimmerman M, Chen Y, Chen YX, Toosky MN, Gardner M, Pan M, Li YY, Kawaji Q, Zhu JH, Su HW, Martinot AJ, Rubin EJ, Dartois VA, Javid B. 2018. Kasugamycin potentiates rifampicin and limits emergence of resistance in *Mycobacterium tuberculosis* by specifically decreasing mycobacterial mistranslation. *Elife* 7:e36782. <https://doi.org/10.7554/eLife.36782>.
 17. Liu J, Gefen O, Ronin I, Bar-Meir M, Balaban NQ. 2020. Effect of tolerance on the evolution of antibiotic resistance under drug combinations. *Science* 367:200–204. <https://doi.org/10.1126/science.aay3041>.
 18. Balaban NQ, Helaine S, Lewis K, Ackermann M, Aldridge B, Andersson DI, Brynildsen MP, Bumann D, Camilli A, Collins JJ, Dehio C, Fortune S, Ghigo JM, Hardt WD, Harms A, Heinemann M, Hung DT, Jenal U, Levin BR, Michiels J, Storz G, Tan MW, Tenson T, Van Melderen L, Zinkernagel A. 2019. Definitions and guidelines for research on antibiotic persistence. *Nat Rev Microbiol* 17:441–448. <https://doi.org/10.1038/s41579-019-0196-3>.
 19. Keren I, Minami S, Rubin E, Lewis K. 2011. Characterization and transcriptome analysis of *Mycobacterium tuberculosis* persisters. *mBio* 2:e00100-11. <https://doi.org/10.1128/mBio.00100-11>.
 20. Fridman O, Goldberg A, Ronin I, Shosh N, Balaban NQ. 2014. Optimization of lag time underlies antibiotic tolerance in evolved bacterial populations. *Nature* 513:418–421. <https://doi.org/10.1038/nature13469>.
 21. Dengler Haunreiter V, Boumasmoud M, Haffner N, Wipfli D, Leimer N, Rachmuhl C, Kuhnert D, Achermann Y, Zbinden R, Benussi S, Vulin C, Zinkernagel AS. 2019. In-host evolution of *Staphylococcus epidermidis* in a pacemaker-associated endocarditis resulting in increased antibiotic tolerance. *Nat Commun* 10:1149. <https://doi.org/10.1038/s41467-019-09053-9>.
 22. Sohaskey CD, Voskuil MI. 2015. In vitro models that utilize hypoxia to induce non-replicating persistence in Mycobacteria. *Methods Mol Biol* 1285:201–213. https://doi.org/10.1007/978-1-4939-2450-9_11.
 23. Jarvis B, Wilrich C, Wilrich PT. 2010. Reconsideration of the derivation of most probable numbers, their standard deviations, confidence bounds and rarity values. *J Appl Microbiol* 109:1660–1667. <https://doi.org/10.1111/j.1365-2672.2010.04792.x>.
 24. Saito K, Warrier T, Somersan-Karakaya S, Kaminski L, Mi J, Jiang X, Park S, Shigyo K, Gold B, Roberts J, Weber E, Jacobs WR, Jr, Nathan CF. 2017. Rifamycin action on RNA polymerase in antibiotic-tolerant *Mycobacterium tuberculosis* results in differentially detectable populations. *Proc Natl Acad Sci U S A* 114:E4832–E4840. <https://doi.org/10.1073/pnas.1705385114>.
 25. Chengalroyen MD, Beukes GM, Gordhan BG, Streicher EM, Churchyard G, Hafner R, Warren R, Otzombe K, Martinson N, Kana BD. 2016. Detection and quantification of differentially culturable tubercle bacteria in sputum from patients with tuberculosis. *Am J Respir Crit Care Med* 194:1532–1540. <https://doi.org/10.1164/rccm.201604-0769OC>.
 26. Penuelas-Urquides K, Villarreal-Trevino L, Silva-Ramirez B, Rivadeneyra-Espinoza L, Said-Fernandez S, de Leon MB. 2013. Measuring of *Mycobacterium tuberculosis* growth. A correlation of the optical measurements with colony forming units. *Braz J Microbiol* 44:287–289. <https://doi.org/10.1590/S1517-83822013000100042>.
 27. de Steenwinkel JE, Aarnoutse RE, de Knecht GJ, ten Kate MT, Teulen M, Verbrugh HA, Boeree MJ, van Soolingen D, Bakker-Woudenberg IA. 2013. Optimization of the rifampin dosage to improve the therapeutic efficacy in tuberculosis treatment using a murine model. *Am J Respir Crit Care Med* 187:1127–1134. <https://doi.org/10.1164/rccm.201207-1211OC>.
 28. Ocheretina O, Escuyer VE, Mabou MM, Royal-Mardi G, Collins S, Vilbrun SC, Pape JW, Fitzgerald DW. 2014. Correlation between genotypic and phenotypic testing for resistance to rifampin in *Mycobacterium tuberculosis* clinical isolates in Haiti: investigation of cases with discrepant susceptibility results. *PLoS One* 9:e90569. <https://doi.org/10.1371/journal.pone.0090569>.
 29. Brauner A, Shosh N, Fridman O, Balaban NQ. 2017. An experimental framework for quantifying bacterial tolerance. *Biophys J* 112:2664–2671. <https://doi.org/10.1016/j.bpj.2017.05.014>.
 30. Srinivasan V, Ha VTN, Vinh DN, Thai PVK, Ha DTM, Lan NH, Hai HT, Walker TM, Thu DDA, Dunstan SJ, Thwaites GE, Ashton PM, Caws M, Thuong NTT. 2020. Sources of multi-drug resistance in patients with previous isoniazid resistant tuberculosis identified using whole genome sequencing: a longitudinal cohort study. *Clin Infect Dis* 2020:ciaa254. <https://doi.org/10.1093/cid/ciaa254>.
 31. Gefen O, Chekol B, Strahilevitz J, Balaban NQ. 2017. TDtest: easy detection of bacterial tolerance and persistence in clinical isolates by a modified disk-diffusion assay. *Sci Rep* 7:41284. <https://doi.org/10.1038/srep41284>.
 32. Cheng Y, Xie J, Lee KH, Gaur RL, Song A, Dai T, Ren H, Wu J, Sun Z, Banai N, Akin D, Rao J. 2018. Rapid and specific labeling of single live *Mycobacterium tuberculosis* with a dual-targeting fluorogenic probe. *Sci Transl Med* 10:ear4470. <https://doi.org/10.1126/scitranslmed.aar4470>.
 33. Imperial MZ, Nahid P, Phillips PPJ, Davies GR, Fielding K, Hanna D, Hermann D, Wallis RS, Johnson JL, Lienhardt C, Savic RM. 2018. A patient-level pooled analysis of treatment-shortening regimens for drug-susceptible pulmonary tuberculosis. *Nat Med* 24:1708–1715. <https://doi.org/10.1038/s41591-018-0224-2>.
 34. Vijay S, Vinh DN, Hai HT, Ha VTN, Dung VTM, Dinh TD, Nhung HN, Tram TTB, Aldridge BB, Hanh NT, Thu DDA, Phu NH, Thwaites GE, Thuong NTT. 2017. Influence of stress and antibiotic resistance on cell-length distribution in *Mycobacterium tuberculosis* clinical isolates. *Front Microbiol* 8:2296. <https://doi.org/10.3389/fmicb.2017.02296>.
 35. Demirdjian S, Sanchez H, Hopkins D, Berwin B. 2019. Motility-independent formation of antibiotic-tolerant *Pseudomonas aeruginosa* aggregates. *Appl Environ Microbiol* 85:e00844-19. <https://doi.org/10.1128/AEM.00844-19>.
 36. Hai HT, Vinh DN, Thu DDA, Hanh NT, Phu NH, Srinivasan V, Thwaites GE, Thuong NTT. 2019. Comparison of the *Mycobacterium tuberculosis* molecular bacterial load assay, microscopy and GeneXpert versus liquid culture for viable bacterial load quantification before and after starting pulmonary tuberculosis treatment. *Tuberculosis (Edinb)* 119:101864. <https://doi.org/10.1016/j.tube.2019.101864>.